Walleye Capital LLC purchased a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 23,543 shares of the biotechnology company’s stock, valued at approximately $1,083,000.
Several other hedge funds also recently modified their holdings of the company. BlackRock Inc. increased its position in shares of Arrowhead Pharmaceuticals by 1.2% during the 1st quarter. BlackRock Inc. now owns 12,155,084 shares of the biotechnology company’s stock valued at $559,014,000 after purchasing an additional 147,021 shares during the period. Vanguard Group Inc. grew its holdings in shares of Arrowhead Pharmaceuticals by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 9,718,250 shares of the biotechnology company’s stock worth $446,943,000 after acquiring an additional 78,107 shares during the last quarter. State Street Corp grew its holdings in shares of Arrowhead Pharmaceuticals by 19.9% in the 1st quarter. State Street Corp now owns 4,681,955 shares of the biotechnology company’s stock worth $215,323,000 after acquiring an additional 777,184 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of Arrowhead Pharmaceuticals by 154.0% in the 4th quarter. Alliancebernstein L.P. now owns 2,464,511 shares of the biotechnology company’s stock worth $163,397,000 after acquiring an additional 1,494,218 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Arrowhead Pharmaceuticals by 1.2% in the 1st quarter. Invesco Ltd. now owns 2,334,074 shares of the biotechnology company’s stock worth $107,345,000 after acquiring an additional 28,433 shares during the last quarter. 67.29% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on ARWR. Morgan Stanley began coverage on Arrowhead Pharmaceuticals in a report on Friday, September 9th. They issued an “equal weight” rating and a $41.00 target price on the stock. StockNews.com upgraded Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 23rd. HC Wainwright reiterated a “buy” rating and set a $110.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 14th. Chardan Capital lifted their price target on Arrowhead Pharmaceuticals from $80.00 to $82.00 in a report on Friday, August 5th. Finally, The Goldman Sachs Group lifted their price target on Arrowhead Pharmaceuticals from $58.00 to $65.00 and gave the company a “buy” rating in a report on Monday, August 8th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $66.57.
Arrowhead Pharmaceuticals Price Performance
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) last released its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The firm had revenue of $32.41 million for the quarter, compared to analyst estimates of $52.61 million. Arrowhead Pharmaceuticals had a negative net margin of 61.58% and a negative return on equity of 36.05%. Arrowhead Pharmaceuticals’s revenue for the quarter was down 29.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.29) EPS. Analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -1.29 EPS for the current fiscal year.
Arrowhead Pharmaceuticals Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma.
- Get a free copy of the StockNews.com research report on Arrowhead Pharmaceuticals (ARWR)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.